Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: February 3, 2023

Details for Patent: 9,296,782

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,296,782 protect, and when does it expire?

Patent 9,296,782 protects VOSEVI and is included in one NDA.

This patent has eighty-seven patent family members in forty-one countries.

Summary for Patent: 9,296,782
Title:Inhibitors of hepatitis C virus
Abstract: Compounds of Formula I are disclosed ##STR00001## As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
Inventor(s): Bjornson; Kyla (San Lorenzo, CA), Canales; Eda (San Mateo, CA), Cottell; Jeromy J. (Redwood City, CA), Karki; Kapil Kumar (Foster City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Kobayashi; Tetsuya (Sunnyvale, CA), Link; John O. (San Francisco, CA), Martinez; Ruben (South San Francisco, CA), Phillips; Barton W. (San Mateo, CA), Pyun; Hyung-Jung (Fremont, CA), Sangi; Michael (Oakland, CA), Schrier; Adam James (Redwood City, CA), Siegel; Dustin (Foster City, CA), Taylor; James G. (San Mateo, CA), Tran; Chinh Viet (San Diego, CA), Trejo Martin; Teresa Alejandra (Union City, CA), Vivian; Randall W. (San Mateo, CA), Yang; Zheng-Yu (Palo Alto, CA), Zablocki; Jeff (Los Altos, CA), Zipfel; Sheila (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/934,090
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,296,782

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,296,782

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3903 See Plans and Pricing
Argentina 091661 See Plans and Pricing
Australia 2013286729 See Plans and Pricing
Australia 2016200201 See Plans and Pricing
Australia 2016200670 See Plans and Pricing
Australia 2017203984 See Plans and Pricing
Australia 2019222909 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.